ArticleRisk analysis : an official publication of the Society for Risk Analysis2021
Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens (Basel, Switzerland) · 2024Pooled it
- Article
- Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.Vaccine · 2025Article
- Assessing early detection ability through spatial arrangements in environmental surveillance for poliovirus: A simulation-based study.PloS one · 2025Article
- Securing the Future: Strategies for Global Polio Vaccine Security Amid Eradication Efforts.Vaccines · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.Vaccine · 2023Article
- Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.Expert review of vaccines · 2022Article
- Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.Open forum infectious diseases · 2021Article
- No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.].Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- An Updated Economic Analysis of the Global Polio Eradication Initiative.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Modeling and Managing Poliovirus Risks: We are Where we are….Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine.Vaccines · 2020Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.Medical decision making : an international journal of the Society for Medical Decision MakingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Countries face different poliovirus risks, which imply different benefits associated with continued and future use of oral poliovirus vaccine (OPV) and/or inactivated poliovirus vaccine (IPV). With the Global Polio Eradication Initiative (GPEI) continuing to extend its timeline for ending the transmission of all wild polioviruses and to introduce new poliovirus vaccines, the polio vaccine supply chain continues to expand in complexity. The increased complexity leads to significant uncertainty about supply and costs. Notably, the strategy of phased OPV cessation of all three serotypes to stop all future incidence of poliomyelitis depends on successfully stopping the transmission of all wild polioviruses. Countries also face challenges associated with responding to any outbreaks that occur after OPV cessation, because stopping transmission of such outbreaks requires reintroducing the use of the stopped OPV in most countries. National immunization program leaders will likely consider differences in their risks and willingness-to-pay for risk reduction as they evaluate their investments in current and future polio vaccination. Information about the costs and benefits of future poliovirus vaccines, and discussion of the complex situation that currently exists, should prove useful to national, regional, and global decisionmakers and support health economic modeling. Delays in achieving polio eradication combined with increasing costs of poliovirus vaccines continue to increase financial risks for the GPEI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.